Associated Papers
Impact of Complex Genetic and Drug-Drug Interactions on Tamoxifen Metabolism and Efficacy.
Saad I et al.
Journal of Personalized Medicine, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
Whole exome sequencing reveals an FCGBP variant associated with spontaneous intraabdominal hemorrhage in severe acute pancreatitis.
Tang QY et al.
Imetaomics, 2025
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
Helland T et al.
Journal of Personalized Medicine, 2021
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients.
Ahmed JH et al.
Cancers, 2019
Pharmacogenetics of ugt genes in North African populations.
Gaibar M et al.
The Pharmacogenomics Journal, 2018
Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.
Woo HI et al.
Oncotarget, 2017
A germline predictive signature of response to platinum chemotherapy in esophageal cancer.
Rumiato E et al.
Translational Research : the Journal of Laboratory and Clinical Medicine, 2016
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
Del Re M et al.
Pharmacological Research, 2016
XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine.
Talukder AK et al.
Plos One, 2015
Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
Romero-Lorca A et al.
Plos One, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
Human hepatic UGT2B15 developmental expression.
Divakaran K et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2014
The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.
Angstadt AY et al.
Genes, Chromosomes & Cancer, 2014
Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation.
Hanioka N et al.
Archives of Toxicology, 2011
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
He X et al.
British Journal of Clinical Pharmacology, 2009
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Japanese single nucleotide polymorphism database for 267 possible drug-related genes.
Iida A et al.
Cancer Science, 2006
UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
Court MH et al.
The Journal of Pharmacology and Experimental Therapeutics, 2004
[SNP collection, pharmacogenomics, and the future of drug therapy].
Iida A et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2002
Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8.
Iida A et al.
Journal of Human Genetics, 2002